Literature DB >> 11956640

Carboplatin/etoposide induces remission of metastasised malignant peripheral nerve tumours (malignant schwannoma) refractory to first-line therapy.

Martin B Steins1, Hubert Serve, Michael Zühlsdorf, Norbert Senninger, Michael Semik, Wolfgang E Berdel.   

Abstract

Malignant peripheral nerve tumours (MPNT), e.g. malignant schwannoma, represent a relatively rare tumour entity which is usually regarded as a member of the group of soft-tissue sarcomas and treated accordingly. For chemotherapeutic approaches in metastasised disease, ifosfamide and doxorubicin have been identified as the most efficient agents, with overall response rates distinctly less than 50%. In case of non-response, recommendations for effective second-line regimens are lacking. We present the case histories of two patients with pulmonary metastasised MPNT that was primarily refractory to ifosfamide/doxorubicin. Both patients developed a partial remission with tumour reduction exceeding 50% after treatment with carboplatin in combination with etoposide (CE), 150 mg/m2 each, days 1-4 in 4-week intervals. Complete resectability of lung metastases could be achieved, with histologic evidence for advanced tumour regression at the time of resection. Patients remain in stable complete remission 20 and 28 months after surgery, respectively. Major CE-associated toxicity was cumulative myelosuppression, especially thrombocytopenia, reaching WHO grade 4. To our knowledge, this is the first report showing that CE is a possibly successful chemotherapeutic regimen in advanced MPNT, although further studies are necessary to evaluate its efficacy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956640

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  11 in total

1.  Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy.

Authors:  Yoshiaki Kinebuchi; Wataru Noguchi; Yasuhiko Igawa; Osamu Nishizawa
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

2.  First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study.

Authors:  J R Kroep; M Ouali; H Gelderblom; A Le Cesne; T J A Dekker; M Van Glabbeke; P C W Hogendoorn; P Hohenberger
Journal:  Ann Oncol       Date:  2010-07-23       Impact factor: 32.976

3.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

Review 4.  Malignant peripheral nerve sheath tumors.

Authors:  Mohamad Farid; Elizabeth G Demicco; Roberto Garcia; Linda Ahn; Pamela R Merola; Angela Cioffi; Robert G Maki
Journal:  Oncologist       Date:  2014-01-27

Review 5.  Systemic Options for Malignant Peripheral Nerve Sheath Tumors.

Authors:  Ayesha Hassan; Roberto Carmagnani Pestana; Amanda Parkes
Journal:  Curr Treat Options Oncol       Date:  2021-02-27

6.  Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma.

Authors:  Charles C Vining; Phillip J Hsu; Aaron Miller; Daniel J Olson; Thomas F Gajewski; Peter Pytel; Bruce S Bauer; Michael J Millis; Kevin K Roggin
Journal:  Melanoma Res       Date:  2021-02-01       Impact factor: 3.199

Review 7.  Non-gastrointestinal stromal tumours soft tissue sarcomas: an update.

Authors:  Gustavo Duarte Ramos Matos; Veridiana Pires de Camargo; Rodrigo Ramella Munhoz; Gilberto de Castro
Journal:  Ecancermedicalscience       Date:  2019-08-13

8.  Malignant peripheral nerve sheath tumor in neurobifromatosis type-1: two case reports.

Authors:  Christos Kosmas; George Tsakonas; Katerina Evgenidi; Argyris Gassiamis; Lefkothea Savva; Nikolaos Mylonakis; Athanasios Karabelis
Journal:  Cases J       Date:  2009-06-09

9.  Can Discord Domain-Containing Receptor 2 Mutation Act as a Disease Modifier for PRKAR1A Associated Melanotic Schwannoma?

Authors:  Erica M Roman Hernandez; Sri Laxmi Valasareddi; Jarrod Adkison; Henna Awan; Krishnamohan R Basarakodu; Arash Velayati
Journal:  Case Rep Oncol       Date:  2021-06-11

10.  Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection.

Authors:  Matthias Kolberg; Maren Høland; Guro E Lind; Trude H Ågesen; Rolf I Skotheim; Kirsten Sundby Hall; Nils Mandahl; Sigbjørn Smeland; Fredrik Mertens; Ben Davidson; Ragnhild A Lothe
Journal:  Mol Oncol       Date:  2015-02-18       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.